Table 5 Univariate survival analysis (overall mortality by patient subgroups)

From: PD-1 (PDCD1) promoter methylation in Merkel cell carcinoma: prognostic relevance and relationship with clinico-pathological parameters

 

Proportion of deceased, n (%)

log-rank test: χ2; p-value

Permutation test: p-value

mPDCD1high

18/35(51)

5.17; 0.023

0.023

Age > 75 years

24/35(69)

1.14; 0.285

0.289

Male sex

22/35(63)

0.65; 0.419

0.420

Size > 2 cm

24/35(69)

5.66; 0.017

0.019

Tumor thickness > 10 mm

21/33(64)

0.89; 0.347

0.353

Angioinvasion

24/33(73)

3.28; 0.070

0.077

Mitosis > 10/HPF

21/35(60)

0.02; 0.881

0.878

Ki67 > 50%

19/35(54)

0.29; 0.591

0.593

Immune cells

14/35(40)

2.52; 0.112

0.115

Merkel cell polyomavirus

11/35(31)

10.28;0.001

0.001

Infiltrative growth

13/33(39)

1.15; 0.285

0.284

PD-L1 immune cells 5-100%

13/35(37)

1.05; 0.306

0.306

PD-L1 tumor 5-100%

9/35(26)

2.83; 0.093

0.090

PD-L1 global

16/35(46)

1.40; 0.236

0.239

Clinical stage III-IV

15/35(43)

2.77; 0.096

0.094

Site

 

0.01; 0.997

0.998

head&neck

14/35(40)

  

extremities

13/35(37)

  

Trunk

8/35(23)

  
  1. n: number of patients for which clinico-pathological features was present and/or evaluated (among the 35 deceased patients); mPDCD1high: high level of mPDCD1; HPF high-power field
Back to article page